FIA
SYRE icon

FNY Investment Advisers’s Spyre Therapeutics SYRE Stock Holding History

FNY Investment Advisers’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-60
Closed -$11K – 960
2021
Q1 		$11K Buy
+60
New +$11.5K ﹤0.01% 569

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FNY Investment Advisers's SYRE Position: Q2 2021 in Review

FNY Investment Advisers sold out of Spyre Therapeutics (SYRE) in Q2 2021, closing a stake of 60 shares — an estimated $11K sold.

FNY Investment Advisers first reported a position in SYRE in Q1 2021 and held it in 1 quarter. The position peaked at $11K in Q1 2021. 78 funds tracked by Wall St. Rank hold SYRE as of Q2 2021.

  • FNY Investment Advisers reported no remaining Spyre Therapeutics position as of Q2 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 60 Spyre Therapeutics shares in Q2 2021, an estimated $11K.
  • FNY Investment Advisers first reported a position in Spyre Therapeutics in Q1 2021 and held it in 1 quarter.
  • FNY Investment Advisers's Spyre Therapeutics position peaked at $11K in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2021.

Based on FNY Investment Advisers's 13F filing for Q2 2021, filed 14 Jul 2021.